| Alzheimer's Disease
Namzaric vs Leqembi
Side-by-side clinical, coverage, and cost comparison for alzheimer's disease.Deep comparison between: Namzaric vs Leqembi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLeqembi has a higher rate of injection site reactions vs Namzaric based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Leqembi but not Namzaric, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Namzaric
Leqembi
At A Glance
Oral
Once daily
NMDA antagonist / AChE inhibitor
IV infusion
Every 2 weeks
Anti-amyloid beta antibody
Indications
- Alzheimer's Disease
- Alzheimer's Disease
Dosing
Alzheimer's Disease Recommended starting dose 7 mg/10 mg once daily in the evening; increase in 7 mg increments at minimum weekly intervals to maintenance dose of 28 mg/10 mg once daily in the evening.
Alzheimer's Disease, Severe Renal Impairment Recommended maintenance dose is 14 mg/10 mg once daily in the evening for patients with severe renal impairment (creatinine clearance 5-29 mL/min).
Alzheimer's Disease Starting dosage: 10 mg/kg IV infusion once every 2 weeks over approximately one hour; maintenance dosage: 10 mg/kg IV infusion once every 4 weeks or 360 mg SC injection once weekly via autoinjector.
Contraindications
- Known hypersensitivity to memantine hydrochloride, donepezil hydrochloride, piperidine derivatives, or any excipient in the formulation
- Serious hypersensitivity to lecanemab-irmb or any excipient of LEQEMBI or LEQEMBI IQLIK (reactions include angioedema and anaphylaxis)
Adverse Reactions
Most common (>=5%) Headache, diarrhea, dizziness (memantine); diarrhea, anorexia, vomiting, nausea, ecchymosis (donepezil, severe AD); insomnia, muscle cramp, fatigue (donepezil, mild to moderate AD).
Serious Cardiovascular conditions, peptic ulcer disease, gastrointestinal bleeding, nausea and vomiting, genitourinary conditions, seizures, pulmonary conditions.
Postmarketing Memantine: acute renal failure, agranulocytosis, congestive cardiac failure, hepatitis, leukopenia, pancreatitis, pancytopenia, Stevens-Johnson syndrome, suicidal ideation, thrombocytopenia, thrombotic thrombocytopenic purpura. Donepezil: abdominal pain, agitation, cholecystitis, confusion, convulsions, hallucinations, heart block, hemolytic anemia, hepatitis, hyponatremia, neuroleptic malignant syndrome, pancreatitis, rash.
Most common (>=5%) Infusion-related reactions, ARIA-H, ARIA-E, headache, superficial siderosis of CNS, rash, nausea/vomiting, cough, diarrhea
Serious Amyloid related imaging abnormalities (ARIA-E, ARIA-H), hypersensitivity reactions, infusion-related reactions
Pharmacology
NAMZARIC combines memantine, a low to moderate affinity uncompetitive NMDA receptor antagonist that blocks excessive glutamatergic activity, and donepezil, a reversible acetylcholinesterase inhibitor that increases central cholinergic transmission by inhibiting hydrolysis of acetylcholine; each component addresses a distinct postulated pathophysiological mechanism in Alzheimer's disease.
Lecanemab-irmb is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, reducing amyloid beta plaques in the brain - a defining pathophysiological feature of Alzheimer's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Namzaric
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Leqembi
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Namzaric
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Leqembi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Namzaric
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Leqembi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Namzaric.
$0/fillfill
Leqembi Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NamzaricView full Namzaric profile
LeqembiView full Leqembi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.